Literature DB >> 9627021

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

D D Gladman1, V T Farewell, K Wong, J Husted.   

Abstract

OBJECTIVE: To investigate prognostic factors associated with mortality in patients with psoriatic arthritis (PsA).
METHODS: Patients followed up at the Toronto PsA Clinic between 1978 and 1994 were included. Patients were reviewed at initial clinic entry and at 6-month intervals using a standard protocol. Data on deaths were collected in a prospective manner, and death certificates were used to identify the primary and antecedent cause(s) of death. All death information was recorded in the clinic's computerized database. Only factors that represented standard clinical measures of disease activity and progression were studied. The relationship between potential prognostic factors recorded at the time of the first clinic visit and the mortality rate was determined using the Cox relative risk regression model.
RESULTS: There were 428 patients (234 men and 194 women), of whom 68% were known to be alive on September 1, 1994, 20% were lost to followup but assumed to be alive, and 12% had died. Multivariate analysis revealed that an erythrocyte sedimentation rate (ESR) > 15 mm/hour, medications used prior to initial clinic visit, radiologic damage, and the absence of nail lesions were associated with an increased overall mortality rate. There is some suggestion that prior medication use was least important for deaths associated with the circulatory system, while radiologic damage was particularly important for such deaths. A marked sex-associated effect was noted among deaths caused by injuries/poisoning, since 6 of the deaths occurred in men and only 1 was in a woman.
CONCLUSION: Patients with PsA are at an increased risk of death compared with the general population. Evidence of previously active and severe disease, as manifested by the prior use of medications and by radiologic changes as well as an elevated ESR at presentation, are prognostic indicators for death. The presence of nail lesions appears to be a protective factor that has the most clinical importance in the context of previously active and severe disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627021     DOI: 10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  80 in total

1.  The burden of psoriatic arthritis: a literature review from a global health systems perspective.

Authors:  Seina Lee; Alan Mendelsohn; Evelyn Sarnes
Journal:  P T       Date:  2010-12

2.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors:  A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

3.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

Review 4.  Psoriatic arthritis: current topics.

Authors:  David McCarey; Iain B McInnes
Journal:  Curr Rheumatol Rep       Date:  2007-12       Impact factor: 4.592

5.  Classification and categorisation of psoriatic arthritis.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  Clin Rheumatol       Date:  2008-07-16       Impact factor: 2.980

6.  Can we identify psoriatic arthritis early?

Authors:  Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2008-12       Impact factor: 4.592

7.  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.

Authors:  Floranne C Wilson; Murat Icen; Cynthia S Crowson; Marian T McEvoy; Sherine E Gabriel; Hilal Maradit Kremers
Journal:  Arthritis Rheum       Date:  2009-02-15

Review 8.  [Psoriatic arthritis. Treatment outcome parameters].

Authors:  E Märker-Hermann; F Behrens
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 9.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

10.  HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population.

Authors:  Markéta Fojtíková; Jirí Stolfa; Peter Novota; Pavlína Cejková; Ctibor Dostál; Marie Cerná
Journal:  Rheumatol Int       Date:  2009-01-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.